LIVE Q&A
Please submit your questions via , and see below for what we've got queued up to start; recent Position Monitor updates will be covered.
|
Hedgeye House Call + Q&A | The Doctor is In | Title Please join us on Monday, May 9 at 2 PM ET - Add to Outlook Health Care Subscribers: CLICK HERE for event details (includes video and materials link) |
THEME & TICKER UPDATES For Monday
We'll review the latest Macro, Industry, Factor, and Stock level details relating to our coverage of the US Medical Economy.
EYE - National Vision is down 18% from where we promoted it to an active short in early April. Mobility data has weakened for Optometrists, and as one of the more consumer-sensitive names on our list, that's not surprising. Earnings are coming up.
LFST - We've been on the phone lately with former LifeStance therapists and owners of acquired practices. The comments have been less than positive on operations and retention. We'll touch on our tracker for LFST and what it says about the prospects for an acceleration of the growth rate through hiring, retention, and acquisitions.
AMN - The short is playing out as we expected as contract labor pricing eases. Registered Nurse scarcity is real and long term and AMN will be a Long at a price, but not until we see the lows in the post COVID pricing trend.
HCA - Data updates continue to come our way on non-COVID volume. We think non-COVID volume is easier to manage from a labor standpoint. COVID is on the rise again, although against less social distancing and higher mobility, maybe it should already be worse.
ATIP - As non-COVID hospital volume picks up and pent-up demand melts, physical therapy will benefit. We've heard plenty of comments that patient volumes are recovering. ATIP finally hired a CEO and will report 1Q22 Monday after the close. After experiencing technical problems with our tracker data, we expect to finally have the update out over the weekend.
DRIO - The pair Short TDOC/Long DRIO has only half worked. 1Q22 is the big quarter where we see the new B2B strategy shift in full. While Quad 4 has ravaged the price, fundamentals have played out as we expected.
Q&A - This is always the best part of the show. We learn a lot by answering your questions. Please feel free to send your questions in ahead of time and we'll make sure they are in the queue and asked and answered.
As always, all data is available upon request, and reach out to with any inquiries.
Thomas Tobin
Managing Director
Twitter
LinkedIn
